Common Contracts
9 similar Control Agreement contracts by Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. Severance & Change in Control AgreementControl Agreement • February 22nd, 2022 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Masaru Matsuda (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware company (the “Company”), and is effective as of the date that this Agreement is signed (the “Effective Date”).
Arcutis Biotherapeutics, Inc. Severance & Change in Control AgreementControl Agreement • February 16th, 2021 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Matthew R. Moore (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the date that Executive commences employment with the Company (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Kenneth A. Lock (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between John W. Smither (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Todd Franklin Watanabe (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Patricia A. Turney (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between David W. Osborne (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 21st, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between Howard G. Welgus (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
ARCUTIS BIOTHERAPEUTICS, INC. SEVERANCE & CHANGE IN CONTROL AGREEMENTControl Agreement • January 6th, 2020 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Severance & Change in Control Agreement (the “Agreement”), is entered into by and between ________________ (the “Executive”) and Arcutis Biotherapeutics, Inc., a Delaware (the “Company”), and is effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s Common Stock is declared effective by the United States Securities and Exchange Commission (the “IPO Date”), or, if later, the date that this Agreement is signed (the “Effective Date”).
